Renal (Kidney) Cancer

Afinitor and Nexavar or Votrient – pro

Everolimus has been approved by the US Food and Drug Administration (FDA) as the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. The NCCN lists it for both first and second line therapy. The approach of tailoring treatment with this drug in combination with other biologicals based on molecular profiles is potentially promising but it is not supported by the

Read more
Cryoablation of kidney cancer – pro

Standard approach to kidney cancers is surgical resection, usually a complete nephrectomy, although partial nephrectomies are sometimes done when sparing renal function is imperative. Small renal masses have recently been treated by cryoablation (freezing to at least -19.4 °C using liquid nitrogen or argon). In cryoablation, a small freezing probe is insertead through the skin, and its tip is placed into the cancerous tissue using CT and ultrasound

Read more
Chromophobe (ChRCC) Type Renal Cell Cancer – pro

Chromophobe(ChRCC) renal cell cancer is rare.  Unfortunately, there are no proven treatment for the metastatic disease. At one time chemotherapy was thought to be effective but  studies did not confirm it. Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR

Read more